Biomea Fusion (BMEA) announced that the World Health Organization, WHO, has approved “icovamenib” as the International Nonproprietary Name, INN, for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted “icovamenib” as the United States Adopted Name, USAN, for BMF-219. The suffix ‘-menib’ stands for menin inhibitor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Morning Movers: Arcadium Lithium surges after deal to be acquired
- Biomea Fusion initiated with a Buy at EF Hutton
- Biomea Fusion forms Global Scientific Advisory Board
- Wynn Resorts upgraded, HP Inc. downgraded: Wall Street’s top analyst calls
- Biomea Fusion price target raised to $41 from $21 at Scotiabank